According to a market report by Lucintel, the future of the global rydapt market looks promising with opportunities in the hospital and pharmacy markets. The global rydapt market is expected to grow with a CAGR of 22.7% from 2025 to 2031. The major drivers for this market are the increasing incidence of acute myeloid leukemia, the rising adoption of targeted cancer therapies, and the growing healthcare investments in oncology drugs.
A more
than 150-page report to understand trends, opportunity and forecast in global rydapt
market to 2031 by type (AML and ASM, SM-AHN, or MCL), application (hospital and
pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the
World).
Lucintel
forecasts that, within the type category, AML is expected to witness higher
growth over the forecast period.
Within the
application category, pharmacy is expected to witness higher growth.
Download
sample by clicking on rydapt market.
In terms
of region, North America is expected to witness the highest growth over the
forecast period.
Novartis,
Astellas Pharma, Blueprint Medicines Corporation, Bristol-Myers Squibb, Jazz
Pharmaceuticals are the major suppliers in the rydapt market.
This unique research
report will enable you to make confident business decisions in this globally competitive
marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
GMP LVV Production Service Market
High Visibility Rain Jacket Market
No comments:
Post a Comment